Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It also provides FemBloc, a non-surgical female permanent birth control solution. The company offers its products to gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.…
Femasys Announces Financial Results for Quarter Ended September 30, 2026 and Provides Corporate Update
Femasys (NASDAQ: FEMY) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 51 employees.
The shares were at 1.240 USD on 20 November 2026, down 94.0% over 52 weeks. Its 52-week range is 1.070 USD to 22.20 USD: the price is 94.4% below the high and 15.9% above the low.
Its market capitalisation is 10.73M USD.
Femasys reports return on equity of -317.4% and revenue down 18.9% year over year.
Its debt exceeds its cash by 3.35M USD, a debt-to-equity ratio of 0.80. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.